Form 4: Akebia CFO Erik Ostrowski Granted Significant Equity Awards

Akebia Therapeutics' SVP, CFO, CBO & Treasurer, Erik Ostrowski, was granted 204,000 restricted stock units and options to purchase 320,000 shares of common stock.

Summary

• Erik Ostrowski, SVP, CFO, CBO & Treasurer of Akebia Therapeutics, Inc. (AKBA), was granted 204,000 shares of common stock in the form of restricted stock units (RSUs) on January 30, 2026.
• These RSUs were granted pursuant to the Issuer's 2023 Stock Incentive Plan, as amended, and will vest one-third on each of the first, second, and third anniversaries of the grant date, subject to continued service.
• Additionally, Mr. Ostrowski was granted options to purchase 320,000 shares of common stock with an exercise price of $1.41 per share on January 30, 2026.
• These options were also granted under the 2023 Stock Incentive Plan and will vest over four years: 25% on the first anniversary of the grant date, with the remaining 75% vesting in equal quarterly installments thereafter, subject to continued service.
• The options have an expiration date of January 30, 2036.
• Following these transactions, Mr. Ostrowski beneficially owns 707,586 shares of common stock directly and 320,000 derivative securities (stock options) directly.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a routine but positive development, reinforcing management's long-term commitment through significant equity incentives, which is generally favorable for shareholder alignment.

Positives

• The significant equity grants align management's long-term interests with shareholder value, incentivizing sustained performance.
• The vesting schedules for both RSUs and stock options promote executive retention and commitment over several years.

Negatives

• The issuance of new equity awards, while common, represents potential future dilution for existing shareholders upon vesting and exercise.

Risks

• The value of the granted equity awards is subject to the future market price fluctuations of Akebia Therapeutics' common stock.
• Forfeiture risk exists if the reporting person's service with the Issuer terminates before the vesting dates.

Future Outlook

The equity grants are designed to provide long-term incentives for the SVP, CFO, CBO & Treasurer, aligning his financial interests with the company's future performance and strategic objectives over the coming years, particularly through the multi-year vesting schedules.

Industry Context

StockSavvy.ai notes that significant equity grants to key executives are a standard practice in the biotechnology and pharmaceutical industries. This approach is crucial for attracting and retaining top talent, especially given the long development cycles and inherent risks associated with drug discovery and commercialization. Such grants aim to align executive incentives with the long-term success and shareholder value creation of the company.

Comparison to Industry Standards

• Equity grants, including restricted stock units and stock options with multi-year vesting schedules, are a standard compensation mechanism in the biotechnology sector, consistent with practices observed at peer companies to align executive incentives with long-term company performance.

Stakeholder Impact

• Shareholders: Potential for future dilution upon vesting and exercise of awards, but also increased alignment of executive interests with long-term stock performance.
• Employees: Reflects standard executive compensation practices within the company's incentive plans.

Next Steps

• The restricted stock units will vest one-third on the first, second, and third anniversaries of the January 30, 2026 grant date.
• The stock options will vest 25% on the first anniversary of the January 30, 2026 grant date, with the remaining 75% vesting in equal quarterly installments thereafter.

Key Dates

Recommendation

This Form 4 reports a routine equity grant to a key executive, which is a standard compensation practice designed to align management interests with long-term shareholder value. It does not present new information that would fundamentally alter the investment thesis for Akebia Therapeutics, hence a 'hold' recommendation is appropriate.

Keywords

Akebia Therapeutics, AKBA, Erik Ostrowski, SEC Form 4, Equity Grant, Restricted Stock Units, Stock Options, Executive Compensation, Insider Transaction, Biotechnology